🌐 ACHIEVE-1 Decoded: Efficacy & Safety of Orforglipron in Type 2 Diabetes
Dr RR Baliga's "Got Knowledge Doc" Podkast
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
🚨 New Breakthrough in Type 2 Diabetes Care! 💊🧬
The ACHIEVE-1 trial shows that Orforglipron, a once-daily oral, nonpeptide GLP-1 receptor agonist, delivers significant reductions in HbA1c and body weight—without injections and with minimal restrictions! 🌍📉
👨⚕️ 559 patients across 5 countries
⏱️ 40 weeks, 3 dosing arms (3, 12, 36 mg)
📊 HbA1c ↓ by up to 1.48%, weight ↓ up to 7.6%
✅ No severe hypoglycemia
📌 Mild GI side effects during dose titration
This is a potential gamechanger for early T2DM care—simple, effective, and patient-friendly. 🚀
#Type2Diabetes #GLP1 #Orforglipron #Endocrinology #ClinicalTrials #PrecisionMedicine #Innovation #NEJM #ACHIEVE1 #OralTherapeutics 💥